Association for Molecular Pathology v. Myriad Genetics, Inc.

E390992

United States Supreme Court case biotechnology law case patent law case

Association for Molecular Pathology v. Myriad Genetics, Inc. is a landmark 2013 U.S. Supreme Court case that held naturally occurring human genes cannot be patented, reshaping the legal landscape for biotechnology and genetic testing.

Try in SPARQL Jump to: Surface forms Statements Referenced by

All labels observed (2)

Label	Occurrences
Association for Molecular Pathology v. Myriad Genetics, Inc. canonical	3
AMP v. Myriad	1

Statements (49)

Predicate	Object
instanceOf	United States Supreme Court case ⓘ biotechnology law case ⓘ patent law case ⓘ
arguedDate	2013-04-15 ⓘ
citation	569 U.S. 576 ⓘ
country	United States of America ⓘ surface form: United States
court	Supreme Court of the United States ⓘ
decisionDate	2013-06-13 ⓘ
decisionType	unanimous decision ⓘ
docketNumber	12-398 ⓘ
fullName	Association for Molecular Pathology v. Myriad Genetics, Inc. self-link ⓘ
holding	Myriad’s patents on naturally occurring BRCA1 and BRCA2 gene sequences are invalid ⓘ cDNA is patent eligible because it is not naturally occurring ⓘ naturally occurring DNA segments are products of nature and not patent eligible merely because they have been isolated ⓘ
impact	clarified patent eligibility of DNA-related inventions ⓘ increased competition in genetic testing for BRCA mutations ⓘ limited the scope of gene patents in the United States ⓘ reshaped patent strategies in biotechnology ⓘ
issue	patent eligibility of complementary DNA (cDNA) ⓘ patent eligibility of human genes ⓘ patent eligibility of isolated DNA ⓘ
legalPrinciple	laws of nature, natural phenomena, and abstract ideas are not patentable ⓘ products of nature are not patent eligible under 35 U.S.C. § 101 ⓘ
legalSubject	biotechnology ⓘ genetic testing ⓘ intellectual property ⓘ patent law ⓘ
lowerCourt	United States Court of Appeals for the Federal Circuit ⓘ
lowerCourtCitation	689 F.3d 1303 (Fed. Cir. 2012) ⓘ
lowerCourtDecisionDate	2012-08-16 ⓘ
majorityOpinionBy	Clarence Thomas ⓘ
petitioner	American Civil Liberties Union ⓘ Association for Molecular Pathology ⓘ Public Patent Foundation ⓘ
relatedTo	In re Chakrabarty ⓘ surface form: Diamond v. Chakrabarty Mayo Collaborative Services v. Prometheus Laboratories, Inc. ⓘ
respondent	Myriad Genetics ⓘ surface form: Myriad Genetics, Inc. United States Patent and Trademark Office ⓘ University of Utah Research Foundation ⓘ
shortName	Association for Molecular Pathology v. Myriad Genetics, Inc. self-linksurface differs ⓘ surface form: AMP v. Myriad
statuteInterpreted	35 U.S.C. § 101 ⓘ
subjectMatter	BRCA1 gene ⓘ BRCA2 gene ⓘ breast cancer susceptibility genes ⓘ ovarian cancer susceptibility genes ⓘ
topic	gene patenting ⓘ medical diagnostics patents ⓘ
vote	9-0 ⓘ
yearDecided	2013 ⓘ

Referenced by (4)

Full triples — surface form annotated when it differs from this entity's canonical label.

October Term 2012 → includesCase → Association for Molecular Pathology v. Myriad Genetics, Inc. ⓘ

Myriad Genetics → legalCase → Association for Molecular Pathology v. Myriad Genetics, Inc. ⓘ

Association for Molecular Pathology v. Myriad Genetics, Inc. → fullName → Association for Molecular Pathology v. Myriad Genetics, Inc. self-link ⓘ

Association for Molecular Pathology v. Myriad Genetics, Inc. → shortName → Association for Molecular Pathology v. Myriad Genetics, Inc. self-linksurface differs ⓘ

this entity surface form: AMP v. Myriad